Lebrikizumab significantly reduced the rate of asthma exacerbations over 52 weeks in biomarker‐high patients (defined as periostin ≥50 ng/mL or blood eosinophils ≥300 cells/μL) in LAVOLTA I (NCT01867125), but this effect was inconsistently observed in LAVOLTA II (NCT01868061).18 This evidence concerns the gene POSTN and asthma.